Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

A U.S. regulator reportedly plans to unveil a faster approach to approving custom gene-editing treatments for rare diseases. Vinay Prasad, who oversees gene therapies in the U.S. Food and Drug ...